NEW YORK (GenomeWeb News) – Compugen today stated that it has discovered and tested a potential blood-based small cell lung cancer biomarker that is it has named CGEN-438.
 
The proposed biomarker is a splice variant of the delta-like protein 3 precursor, DLL3. Previous observations suggest that DLL3 mutations and over-expression are associated with cancer. But CGEN-438 shares no sequence similarity to the membrane protein DLL3. And, unlike DLL3, CGEN-438 is reportedly secreted into the bloodstream.
 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.